In vivo studies further revealed that 5-formamidoimidazole-4-carboxamide ribotide treatment effectively suppressed tumor growth, with overexpression of METTL1 or BRCA1 reversing the inhibitory effects of 5-formamidoimidazole-4-carboxamide ribotide on tumor growth. Here, METTL1 is linked to neoplasm.